The use of in silico approaches to assess potential adverse reactions of new pharmaceutical substances reduces the risks, financial and time costs, associated with drug development. Using our previously developed method for identifying chemical motifs associated with certain types of undesirable biological activity, we have evaluated the off-target toxicity of clinically investigated pharmaceutical substances that would help to evaluate the potential risks of further research and use in clinical practice. For this purpose, we have created highly specific structural fragments for epidermal growth factor receptor and dipeptidyl peptidase 4 inhibitors, which are two molecular targets associated with a wide range of adverse reactions. A search for compounds containing these fragments was performed among 12,070 entries with information on clinical trials in the PubChem database. We have shown that five compounds entering phase I and II trials may have an unfavorable benefit-risk ratio due to the potential inhibition of at least one of the analyzed enzyme. Incorporating such analytical frameworks into early drug discovery and preclinical assessment could substantially reduce overall development costs and timelines, facilitating the introduction of safer and more cost-effective therapeutic agents.
Download PDF:
Keywords: in silico studies, undesirable molecular targets, “off-target” toxicity, structural fragments, adverse drug reaction
Citation:
Savosina P.I., Filimonov D.A., Druzhilovskiy D.S. (2025) Prediction of potential adverse drug reactions utilizing highly specific structural fragments. Biomeditsinskaya Khimiya, 71(6), .
Savosina P.I. et al. Prediction of potential adverse drug reactions utilizing highly specific structural fragments // Biomeditsinskaya Khimiya. - 2025. - V. 71. -N 6. - P. .
Savosina P.I. et al., "Prediction of potential adverse drug reactions utilizing highly specific structural fragments." Biomeditsinskaya Khimiya 71.6 (2025): .
Savosina, P. I., Filimonov, D. A., Druzhilovskiy, D. S. (2025). Prediction of potential adverse drug reactions utilizing highly specific structural fragments. Biomeditsinskaya Khimiya, 71(6), .
References
Zhai J., Yan H., Zhang J., Yan H., Ma J., Zhang S. (2025) A comprehensive analysis of adverse drug reactions in 2020–2023: case studies. Front. Pharmacol., 16, 1628347. CrossRef Scholar google search
Bennett C.L., Hoque S., Olivieri N., Taylor M.A., Aboulafia D., Lubaczewski C., Bennett A.C., Vemula J., Schooley B., Witherspoon B.J., Godwin A.C., Ray P.S., Yarnold P.R., Ausdenmoore H.C., Fishman M., Herring G., Ventrone A., Aldaco J., Hrushesky W.J., Restaino J., Thomsen H.S., Yarnold P.R., Marx R., Migliorati C., Ruggiero S., Nabhan C., Carson K.R., McKoy J.M., Yang Y.T., Schoen M.W., Knopf K., Martin L., Sartor O., Rosen S., Smith W.K. (2020) Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): a qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 31, 100693. CrossRef Scholar google search
Tan Y., Hu Y., Liu X., Yin Z., Chen X.-W., Liu M. (2016) Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation. Methods, 110, 14–25. CrossRef Scholar google search
Jenkinson S., Schmidt F., Rosenbrier Ribeiro L., Delaunois A., Valentin J.-P. (2020) A practical guide to secondary pharmacology in drug discovery. J. Pharmacol. Toxicol. Methods, 105, 106869. CrossRef Scholar google search
Dey S., Luo H., Fokoue A., Hu J., Zhang P. (2018) Predicting adverse drug reactions through interpretable deep learning framework. BMC Bioinformatics, 19(Suppl 21), 476. CrossRef Scholar google search
Scott C., Dodson A., Saulnier M., Snyder K., Racz R. (2022) Analysis of secondary pharmacology assays received by the US Food and Drug Administration. J. Pharmacol. Toxicol. Methods, 117, 107205. CrossRef Scholar google search
Guggina L.M., Choi A.W., Choi J.N. (2017) EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol. Ther., 5, 135–148. CrossRef Scholar google search
Mascolo A., Rafaniello C., Sportiello L., Sessa M., Cimmaruta D., Rossi F., Capuano A. (2016) Dipeptidyl peptidase (DPP)-4 inhibitor-induced arthritis/arthralgia: a review of clinical cases. Drug Safety, 39(5), 401–407. CrossRef Scholar google search
Noguchi Y., Murayama A., Esaki H., Sugioka M., Koyama A., Tachi T., Teramachi H. (2021) Angioedema caused by drugs that prevent the degradation of vasoactive peptides: a pharmacovigilance database study. J. Clin. Med., 10(23), 5507. CrossRef Scholar google search
Savosina P.I., Druzhilovskiy D.S., Filimonov D.A., Poroikov V.V. (2025) Design of highly specific structural fragments for filtering compounds with undesirable activities. Biomedical Chemistry: Research and Methods, 8(4), e00303. CrossRef Scholar google search
PubChem database. Table of Contents. Clinical trials. Retrieved November 2, 2025, from: https://pubchem.ncbi.nlm.nih.gov/classification/?hid=72& hnid=1856916&cache_uid_type=Compound&alias= PubChem %20Compound%20TOC:%20Clinical%20Trials. Scholar google search
United States Federal Register. Food and Drug Administration. Docket No. FDA–2024–N–3165. Retrieved November 24, 2025, from: https://www.federalregister.gov/d/2024-15371. Scholar google search
US Food and Drug Administration. FDA Drug Shortages. Saxagliptin Tablets. Retrieved November 24, 2025, from: https://www.accessdata.fda.gov/scripts/drugshortages/ dsp_ActiveIngredientDetails.cfm?AI=Saxagliptin+Tablets &st=d&tab=tabs-4&panels=0. Scholar google search
Swanson C.D., Akama-Garren E.H., Stein E.A., Petralia J.D., Ruiz P.J., Edalati A., Lindstrom T.M., Robinson W.H. (2012) Inhibition of epidermal growth factor receptor tyrosine kinase ameliorates collagen-induced arthritis. J. Immunol., 188(7), 3513–3521. CrossRef Scholar google search
Savosina P., Druzhilovskiy D., Filimonov D., Poroikov V. (2024) WWAD: the most comprehensive small molecule World Wide Approved Drug database of therapeutics. Front. Pharmacol., 15, 1473279. CrossRef Scholar google search
Yang F., Takagaki Y., Yoshitomi Y., Ikeda T., Li J., Kitada M., Kumagai A., Kawakita E., Shi S., Kanasaki K., Koya D. (2019) Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res., 79(4), 735–746. CrossRef Scholar google search
FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Retrieved November 2, 2025, from: https://www.fda.gov/drugs/drug-safety-and-availability/ fda-drug-safety-communication-fda-warns-dpp-4-inhibitorstype- 2-diabetes-may-cause-severe-joint-pain. Scholar google search
